Plus Therapeutics (PSTV)
(Delayed Data from NSDQ)
$0.66 USD
-0.08 (-10.97%)
Updated Aug 5, 2025 04:00 PM ET
Pre-Market: $0.70 +0.04 (6.38%) 8:16 AM ET
2-Buy of 5 2
D Value C Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PSTV 0.66 -0.08(-10.97%)
Will PSTV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PSTV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PSTV
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
Plus (PSTV) Upgraded to Buy: Here's Why
PSTV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates
Nutriband Inc. (NTRB) Reports Q1 Loss, Misses Revenue Estimates
The Cooper Companies (COO) Surpasses Q2 Earnings and Revenue Estimates
Other News for PSTV
12 Health Care Stocks Moving In Thursday's Intraday Session
Plus Therapeutics (PSTV) to Introduce CNSide Diagnostics in Texas by August 2025
Plus Therapeutics says CNSide CSF platform will be available for Texas in August
Biotech Continues This Week's Momentum With Another Key Announcement